Alto Neuroscience (NYSE:ANRO) Shares Gap Down - Should You Sell?

Alto Neuroscience logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Alto Neuroscience shares dropped sharply at the open, falling from a prior close of $29.54 to $27.10; they were last reported at $26.29.
  • Analyst sentiment is mixed but leans positive: the consensus is “Moderate Buy” with an average price target of $37.88, despite some Sell ratings.
  • The company reported a quarterly loss of $0.54 per share, beating analysts’ estimate of a $0.67 loss. CFO Nicholas Smith also sold 24,056 shares, cutting his personal stake by 50%.
  • MarketBeat previews top five stocks to own in December.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) gapped down prior to trading on Tuesday. The stock had previously closed at $29.54, but opened at $27.10. Alto Neuroscience shares last traded at $26.2850, with a volume of 18,321 shares.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ANRO. Wedbush increased their target price on shares of Alto Neuroscience from $24.00 to $26.00 and gave the company a "neutral" rating in a research report on Thursday, August 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Alto Neuroscience in a research note on Tuesday, October 27th. Wall Street Zen cut shares of Alto Neuroscience from a "hold" rating to a "sell" rating in a research report on Saturday, September 12th. Zacks Research raised shares of Alto Neuroscience from a "strong sell" rating to a "hold" rating in a report on Thursday, August 20th. Finally, BTIG Research reaffirmed a "buy" rating and set a $37.00 price objective on shares of Alto Neuroscience in a research note on Wednesday, November 11th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $37.88.

View Our Latest Stock Report on Alto Neuroscience

Alto Neuroscience Stock Performance

The firm has a market capitalization of $1.03 billion, a PE ratio of -10.50 and a beta of 1.42. The business's fifty day simple moving average is $26.21 and its 200-day simple moving average is $24.69. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.85 and a current ratio of 18.12.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.13. As a group, equities research analysts expect that Alto Neuroscience, Inc. will post -2.50 EPS for the current year.

Insider Buying and Selling at Alto Neuroscience

In related news, CFO Nicholas Smith sold 24,056 shares of the company's stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $25.82, for a total value of $621,125.92. Following the transaction, the chief financial officer directly owned 24,060 shares of the company's stock, valued at $621,229.20. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.25% of the stock is owned by company insiders.

Institutional Trading of Alto Neuroscience

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sterling Capital Management LLC boosted its stake in shares of Alto Neuroscience by 1,045.7% in the third quarter. Sterling Capital Management LLC now owns 1,054 shares of the company's stock worth $27,000 after buying an additional 962 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Alto Neuroscience by 48,581.8% in the third quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company's stock worth $137,000 after buying an additional 5,344 shares in the last quarter. GK Wealth Management LLC acquired a new position in shares of Alto Neuroscience during the 2nd quarter worth approximately $226,000. Empowered Funds LLC purchased a new stake in Alto Neuroscience in the 3rd quarter valued at $299,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Alto Neuroscience during the first quarter worth about $534,000.

Alto Neuroscience Company Profile

(Get Free Report)

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto's approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Alto Neuroscience Right Now?

Before you consider Alto Neuroscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list.

While Alto Neuroscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines